Biotech entity
340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 9 original sources per story, versus 4.4 across the same-window beat baseline. Across a 41-day span, the pace is roughly 0.3 stories per week.
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Source depth averages 9 original sources per story, versus 4.4 across the same-window beat baseline. Across a 41-day span, the pace is roughly 0.3 stories per week. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. Their average consequence score of 6.5 runs above the beat's 6.3 for that window. We currently track 2 Biotech stories that mention President Donald Trump, published between June 28, 2026 and August 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 195 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering President Donald Trump. Shared-story counts are live from our verified record — not editorial picks.
Tariff Escalates to 200%
The tariff rate doubles to 200% on generic drug imports.
100% Tariff Takes Effect
A 100% duty is imposed on eligible generic drug imports.
Duty‑Free Period Begins
Imported generics enter a two‑year duty‑free window.
Generic Drug Tariff Schedule Announced
The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
Executive Order Tariffs Patented Medicines
President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.
The tariff escalation to 200% on generic drugs by August 2029 also applies to biosimilars, which were initially exempt. For biotech and pharma, this could disrupt outsourcing strategies and market access for follow-on biologics. The timeline analysis details product-level risks.
The $1.4 billion Ebola component of the White House’s war funding request could accelerate development of new vaccines and antivirals, offering a rare bright spot for biopharma firms amid broader fiscal uncertainty.
Source: stcatharinesstandard.ca · yahoo.com
President Donald Trump is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
